Skip to main content Skip to search Skip to main navigation

PMDA: Information on the procedure for remote inspections

In January 2021, the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) published the English translation of the document on remote inspections, Procedure for Remote Inspection as a Part of Compliance Inspection on Drugs and Regenerative Medical Products.

The document describes the specific procedure for a remote inspection in five points.  A further four points clarify how to proceed with the necessary documents. Three points deal with the video conferencing system in more detail.

The procedure is usually as follows:

  1. The PMDA announces the inspection to the applicant as a remote inspection; if necessary, there is a pre-inspection meeting.
  2. The PMDA confirms the schedule of the pre-inspection and the method of presenting documentation approximately one to two months prior to the main inspection.
  3. The applicant grants the inspector access to the cloud system or sends the documentation on CD or DVD to PMDA.
  4. Information on sampling condition/scope of documentation will be provided to the applicant 13 business days prior to the main inspection.
  5. Within 10 business days prior to the main inspection, the applicant shares the documentation with the inspector(s).
  6. A pre-inspection, during which the documents are checked, takes place within 10 business days; if there are any concerns to be examined, the applicant is informed.
  7. During the main inspection using a video conferencing system, documents that could not be reviewed during the pre-inspection will be reviewed and the applicant will be interviewed about the concerns identified during the pre-inspection.
  8. After the inspection, the applicant should take action on the unresolved concerns as soon as possible.

PMDA: Procedure for Remote Inspection as a part of compliance inspection on drugs and regenerative medical product 

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

Outsourced Activities in the GDP Environment Part I: Supplier Management

Outsourced Activities in the GDP Environment Part I: Supplier Management

Supplier management is the systematic management of a company´s relationship with its suppliers. It encompasses supplier qualification and customer audits as described in the following excerpt from GMP:KnowHow Pharmalogistics (GDP).

Read more
How is First Air Verified and Monitored During Aseptic Process Qualification?

How is First Air Verified and Monitored During Aseptic Process Qualification?

Here's the answer:
Read more
FDA: Draft Guidance on Assessing Container Closure Systems for Drugs and Biologics

FDA: Draft Guidance on Assessing Container Closure Systems for Drugs and Biologics

On 14 August 2026, the US Food and Drug Administration (FDA) announced the publication of a new draft guidance document entitled ‘Container Closure Systems for Human Drugs and Biological Products’.

Read more
FDA: New FDA Commissioner Dr. Heidi Overton

FDA: New FDA Commissioner Dr. Heidi Overton

President Donald Trump has named White House aide Heidi Overton to lead the US Food and Drug Administration (FDA). Overton will fill the position previously held by Marty Makary, who left the agency in May. This announcement was made on Trump's Truth Social account on 19 August. Her nomination is subject to confirmation by the Senate.

Read more
IPEC: Stability Guide for Excipients has been Updated

IPEC: Stability Guide for Excipients has been Updated

The IPEC Stability Guide for Pharmaceutical Excipients has been updated and is now available as version 3 (2026), as announced on the IPEC (International Pharmaceutical Excipients Council) website.

Read more
EU: “Forever Chemicals” in a Conflict of Interests

EU: “Forever Chemicals” in a Conflict of Interests

On 14 July 2026, the European Parliamentary Research Service (EPRS) published a comprehensive briefing on PFAS (per- and polyfluoroalkyl substances), also known as ‘forever chemicals’. The document is intended to serve as a technical basis for MEPs in their upcoming political decisions on PFAS regulation and summarises the current state of scientific knowledge, regulation and procedures.

Read more
Previous
Next